Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Hernandez Flores, Georgina ^a   Ortiz Lazareno, Pablo C ^a   Lerma Diaz, Jose M ^a   Dominguez Rodriguez, Jorge R ^a   Jave Suarez, Luis F ^a   Aguilar Lemarroy, Adriana del C ^a   de Celis Carrillo, Ruth ^a   del Toro Arreola, Susana ^b   Castellanos Esparza, Yessica C ^a   Bravo Cuellar, Alejandro ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CISPLATIN; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PENTOXIFYLLINE; PROTEIN BCL 2; PROTEIN BCL XL; SYNAPTOPHYSIN; SYNAPTOTAGMIN I; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; LIPOCORTIN 5; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHODIESTERASE INHIBITOR; PROTEIN BCL X;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IN VITRO STUDY; KERATINOCYTE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENESCENCE; SURVIVAL RATE; TUMOR CELL; UTERINE CERVIX TUMOR; ADULT; CELL AGING; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HELA CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADULT; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CASPASES; CELL AGING; CELL LINE, TUMOR; CISPLATIN; FEMALE; FLOW CYTOMETRY; HELA CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; UTERINE CERVICAL NEOPLASMS;

EID: 81055126911     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-483     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Boulet GA, Horvath CA, Berghmans S, Bogers J. Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev 2008, 17(4):810-817. 10.1158/1055-9965.EPI-07-2865, 18398022.
3. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001, 164(7):1017-1025. 80931, 11314432.
4. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997, 89(6):1845-1853.
5. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35(4):495-516. 10.1080/01926230701320337, 2117903, 17562483.
6. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98(9):2603-2614. 10.1182/blood.V98.9.2603, 11675328.
7. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010, 102(20):1536-1546. 10.1093/jnci/djq364, 2957429, 20858887.
8. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003, 63(11):2705-2715.
9. Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr Opin Genet Dev 2011, 21(1):107-112. 10.1016/j.gde.2010.10.005, 21093253.
10. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis?. Mol Pharmacol 2001, 59(4):657-663.
11. Losa JH, Parada Cobo C, Viniegra JG, Sanchez-Arevalo Lobo VJ, Ramon y Cajal S, Sanchez-Prieto R. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 2003, 22(26):3998-4006. 10.1038/sj.onc.1206608, 12821934.
12. Lerma-Diaz JM, Hernandez-Flores G, Dominguez-Rodriguez JR, Ortiz-Lazareno PC, Gomez-Contreras P, Cervantes-Munguia R, Scott-Algara D, Aguilar-Lemarroy A, Jave-Suarez LF, Bravo-Cuellar A. In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkappaBalpha phosphorylation. Immunol Lett 2006, 103(2):149-158. 10.1016/j.imlet.2005.10.019, 16388856.
13. Gomez-Contreras PC, Hernandez-Flores G, Ortiz-Lazareno PC, Del Toro-Arreola S, Delgado-Rizo V, Lerma-Diaz JM, Barba-Barajas M, Dominguez-Rodriguez JR, Bravo Cuellar A. In vitro induction of apoptosis in U937 cells by perillyl alcohol with sensitization by pentoxifylline: increased BCL-2 and BAX protein expression. Chemotherapy 2006, 52(6):308-315. 10.1159/000096003, 17008791.
14. Hernandez-Flores G, Bravo-Cuellar A, Aguilar-Luna JC, Lerma-Diaz JM, Barba-Barajas M, Orbach-Arbouys S. [In vitro induction of apoptosis in acute myelogenous and lymphoblastic leukemia cells by adriamycine is increased by pentoxifylline]. Presse Med 2010, 39(12):1330-1331. 10.1016/j.lpm.2010.07.013, 20888731.
15. Bravo-Cuellar A, Ortiz-Lazareno PC, Lerma-Diaz JM, Dominguez-Rodriguez JR, Jave-Suarez LF, Aguilar-Lemarroy A, del Toro-Arreola S, de Celis-Carrillo R, Sahagun-Flores JE, de Alba-Garcia JE, et al. Sensitization of cervix cancer cells to Adriamycin by Pentoxifylline induces an increase in apoptosis and decrease senescence. Mol Cancer 2010, 9:114. 10.1186/1476-4598-9-114, 2890603, 20482878.
16. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006, 1(5):2315-2319. 10.1038/nprot.2006.339, 17406473.
17. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70(2):440-446. 10.1158/0008-5472.CAN-09-1947, 20068163.
18. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994, 86(20):1517-1524. 10.1093/jnci/86.20.1517, 7932806.
19. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58(3):621-681. 10.1124/pr.58.3.10, 16968952.
20. Reynolds CP, Maurer BJ. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med 2005, 110:173-183.
21. Martin D, Lenardo M. Morphological, biochemical, and flow cytometric assays of apoptosis. Curr Protoc Mol Biol 2001, 14. Unit 14 13.
22. Geske FJ, Lieberman R, Strange R, Gerschenson LE. Early stages of p53-induced apoptosis are reversible. Cell Death Differ 2001, 8(2):182-191. 10.1038/sj.cdd.4400786, 11313720.
23. Bohm L, Roos WP, Serafin AM. Inhibition of DNA repair by Pentoxifylline and related methylxanthine derivatives. Toxicology 2003, 193(1-2):153-160. 10.1016/S0300-483X(03)00294-4, 14599774.
24. Reddel RR. The role of senescence and immortalization in carcinogenesis. Carcinogenesis 2000, 21(3):477-484. 10.1093/carcin/21.3.477, 10688868.
25. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007, 1775(1):5-20.
26. Campisi J, Kim SH, Lim CS, Rubio M. Cellular senescence, cancer and aging: the telomere connection. Exp Gerontol 2001, 36(10):1619-1637. 10.1016/S0531-5565(01)00160-7, 11672984.
27. Theron T, Bohm L. Influence of the G2 cell cycle block abrogator pentoxifylline on the expression and subcellular location of cyclin B1 and p34cdc2 in HeLa cervical carcinoma cells. Cell Prolif 2000, 33(1):39-50. 10.1046/j.1365-2184.2000.00160.x, 10741643.
28. Theron T, Binder A, Verheye-Dua F, Bohm L. The role of G2-block abrogation, DNA double-strand break repair and apoptosis in the radiosensitization of melanoma and squamous cell carcinoma cell lines by pentoxifylline. Int J Radiat Biol 2000, 76(9):1197-1208. 10.1080/09553000050134438, 10993631.
29. Serafin AM, Binder AB, Bohm L. Chemosensitivity of prostatic tumour cell lines under conditions of G2 block abrogation. Urol Res 2001, 29(3):221-227. 10.1007/s002400100186, 11482451.
30. Rishi L, Gahlot S, Kathania M, Majumdar S. Pentoxifylline induces apoptosis in vitro in cutaneous T cell lymphoma (HuT-78) and enhances FasL mediated killing by upregulating Fas expression. Biochem Pharmacol 2009, 77(1):30-45. 10.1016/j.bcp.2008.09.018, 18851957.
31. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999, 59(13):3077-3083.
32. Horvath B, Vekasi J, Kesmarky G, Toth K. In vitro antioxidant properties of pentoxifylline and vinpocetine in a rheological model. Clin Hemorheol Microcirc 2008, 40(2):165-166.
33. Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 2007, 12(9):1733-1742. 10.1007/s10495-007-0082-8, 17505786.
34. Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, Tridandapani S, Anant S, Kuppusamy P. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007, 6(2):178-184. 10.4161/cbt.6.2.3577, 1852522, 17218783.
35. Yeh PY, Yeh KH, Chuang SE, Song YC, Cheng AL. Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation. J Biol Chem 2004, 279(25):26143-26148. 10.1074/jbc.M402362200, 15073167.
36. Zhang Y, Qu X, Jing W, Hu X, Yang X, Hou K, Teng Y, Zhang J, Liu Y. GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling. Anticancer Drugs 2009, 20(3):208-214. 10.1097/CAD.0b013e328322fbaa, 19396019.
37. Amran D, Sancho P, Fernandez C, Esteban D, Ramos AM, de Blas E, Gomez M, Palacios MA, Aller P. Pharmacological inhibitors of extracellular signal-regulated protein kinases attenuate the apoptotic action of cisplatin in human myeloid leukemia cells via glutathione-independent reduction in intracellular drug accumulation. Biochim Biophys Acta 2005, 1743(3):269-279. 10.1016/j.bbamcr.2004.10.009, 15843040.
38. Deng Q, Liao R, Wu BL, Sun P. High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J Biol Chem 2004, 279(2):1050-1059.
39. Zubova SG, Bykova TV, Zubova Iu G, Romanov VS, Aksenov ND, Pospelov VA, Pospelova TV. [Role of p38alpha kinase in activation of premature senescence program in transformed mouse fibroblasts]. Tsitologiia 2007, 49(2):115-124.
40. Kwong J, Hong L, Liao R, Deng Q, Han J, Sun P. p38alpha and p38gamma mediate oncogenic ras-induced senescence through differential mechanisms. J Biol Chem 2009, 284(17):11237-11246. 2670128, 19251701.
41. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 2008, 233(1):21-31.
42. Fiebig AA, Zhu W, Hollerbach C, Leber B, Andrews DW. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 2006, 6:213. 10.1186/1471-2407-6-213, 1560389, 16928273.
43. Suen DF, Norris KL, Youle RJ. Mitochondrial dynamics and apoptosis. Genes Dev 2008, 22(12):1577-1590. 10.1101/gad.1658508, 2732420, 18559474.
44. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 2004, 6(1):29-40. 1679816, 15068669.
45. Gazzaniga P, Gradilone A, Petracca A, Nicolazzo C, Raimondi C, Iacovelli R, Naso G, Cortesi E. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. J Cell Mol Med 2010, 14(8):2073-2077. 10.1111/j.1582-4934.2010.01117.x, 20597995.
46. Srivastava RK, Sasaki CY, Hardwick JM, Longo DL. Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J Exp Med 1999, 190(2):253-265. 10.1084/jem.190.2.253, 2195578, 10432288.
47. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001, 7(8):2168-2181.
48. Yoon SS, Ahn KS, Kim SH, Shim YM, Kim J. In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype. Lung Cancer 2001, 33(2-3):221-228. 10.1016/S0169-5002(01)00205-7, 11551417.
49. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998, 292(3):435-445. 10.1007/s004410051072, 9582400.
50. Fricker M, Papadia S, Hardingham GE, Tolkovsky AM. Implication of TAp73 in the p53-independent pathway of Puma induction and Puma-dependent apoptosis in primary cortical neurons. J Neurochem 2010, 114(3):772-783. 10.1111/j.1471-4159.2010.06804.x, 2956137, 20477944.
51. Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJ, Seftor RE, Seftor EA, Margaryan NV, Pollock PM, Curtis A, et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 2004, 3(8):895-902.
52. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107(1):257-264. 10.1182/blood-2005-05-2091, 16166592.
53. Sankala HM, Hait NC, Paugh SW, Shida D, Lepine S, Elmore LW, Dent P, Milstien S, Spiegel S. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 2007, 67(21):10466-10474. 10.1158/0008-5472.CAN-07-2090, 17974990.
54. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011, 192(4):547-556. 10.1083/jcb.201009094, 3044123, 21321098.
55. Linskens MH, Harley CB, West MD, Campisi J, Hayflick L. Replicative senescence and cell death. Science 1995, 267(5194):17.